Warning: The NCBI web site requires JavaScript to function. more...
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Fillmore CM, Kuperwasser C.
Breast Cancer Res. 2008;10(2):R25. Epub 2008 Mar 26.
Related citations
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.
Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH.
PLoS One. 2009 Dec 21;4(12):e8377.
[Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].
Lu ZQ, Li HG, Zhang HZ, Fan MJ, Shen XM, He XX.
Ai Zheng. 2008 Jun;27(6):575-9. Chinese.
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.
J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. Epub 2010 Oct 8.
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
Clin Cancer Res. 2009 Jun 15;15(12):4234-41. Epub 2009 Jun 9.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.
Breast Cancer Res. 2008;10(1):R10. Epub 2008 Feb 1.
A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.
Chin Med J (Engl). 2008 Oct 20;121(20):1980-6.
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.
Cancer Res. 2009 Oct 15;69(20):8058-66. Epub 2009 Oct 13.
Identification of pancreatic cancer stem cells.
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM.
Cancer Res. 2007 Feb 1;67(3):1030-7.
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.
Br J Cancer. 2008 Feb 26;98(4):756-65. Epub 2008 Feb 12.
Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.
Vesuna F, Lisok A, Kimble B, Raman V.
Neoplasia. 2009 Dec;11(12):1318-28.
High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL.
J Cell Mol Med. 2009 Aug;13(8B):2236-52. Epub 2008 Aug 4.
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG.
Cancer Immunol Immunother. 2009 Aug;58(8):1185-94. Epub 2008 Dec 2.
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.
Breast Cancer Res. 2006;8(5):R59.
Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model.
Zhou J, Zhang H, Gu P, Margolick JB, Yin D, Zhang Y.
Breast Cancer Res Treat. 2009 May;115(2):269-77. Epub 2008 May 28.
Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri.
Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, Wei H, Tian Z.
Oncol Rep. 2009 Nov;22(5):1129-34.
Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M.
Cancer Sci. 2011 Dec;102(12):2132-8. doi: 10.1111/j.1349-7006.2011.02063.x. Epub 2011 Sep 14.
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.
Breast Cancer Res. 2008;10(3):R53. Epub 2008 Jun 17.
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.
J Natl Cancer Inst. 2008 May 7;100(9):672-9. Epub 2008 Apr 29.
Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression.
Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L, Sun S.
Oncol Rep. 2009 Apr;21(4):1113-21.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on